Browse the evidence

Long-term maintenance of weight loss requires significantly higher physical activity levels (≥150–250 minutes/week) than those recommended for general health or initial weight loss.

To keep weight off, you need to move significantly more than the standard '150 minutes a week' recommendation. Aim for at least 4 hours of moderate activity (like brisk walking) per week. This higher volume is necessary to counteract your body's natural tendency to regain weight after you've lost it.

High-protein diets (>25% of calories or 1-1.2 g/kg body weight) are superior to other macronutrient compositions for long-term weight maintenance, primarily by preserving fat-free mass and increasing satiety.

To keep weight off, prioritize protein in your diet (aim for 1-1.2 grams per kg of your goal body weight). This helps you feel full and protects your muscles, making it easier to stick to your weight loss goals long-term.

Orlistat, taken at 120 mg three times daily, reduces body weight by 8% over 12 months compared to 5% with placebo, and significantly reduces cardiovascular risk factors like hypertension and LDL cholesterol.

Orlistat (120 mg, 3 times daily) helps you lose about 8% of your body weight over a year by blocking fat absorption. It also lowers blood pressure and LDL cholesterol. You must follow a low-fat diet and take vitamin supplements to avoid side effects like oily stools.

Sibutramine, an appetite suppressant acting on the hypothalamus, is more effective than placebo for weight loss when combined with lifestyle changes, with 22-38% of patients achieving >5% weight loss in 3 months.

Sibutramine helps you lose weight by reducing appetite. About 22-38% of users lose more than 5% of their body weight in 3 months. It is not safe for people with heart problems or high cardiovascular risk. Side effects include increased blood pressure and dry mouth.

Bupropion/Naltrexone combination therapy results in a mean weight loss of 6.1% over 56 weeks in obese or overweight adults, significantly better than placebo (1.3%).

Bupropion/Naltrexone helps you lose about 6% of your body weight over a year. It works by reducing appetite and food cravings. It is not safe for people with seizure disorders, uncontrolled high blood pressure, or those taking certain antidepressants. Side effects like nausea are common but often temporary.

Semaglutide (subcutaneous 1 mg/week and oral 14 mg/day) significantly reduces HbA1c and body weight in patients with type 2 diabetes, with subcutaneous administration showing superior efficacy compared to other GLP-1 receptor agonists.

Semaglutide is a highly effective GLP-1 receptor agonist for lowering blood sugar (HbA1c) and reducing body weight in type 2 diabetes patients. It is available in both weekly injections (1 mg) and daily oral tablets (14 mg), with the injection showing slightly greater efficacy. For obese non-diabetics, a higher injection dose (2.4 mg) leads to significant weight loss (~15%). While nausea is a common side effect, it is usually manageable. Patients with pre-existing eye disease (retinopathy) should use it cautiously due to a potential increased risk of retinal complications.

GLP-1 agonists (semaglutide, liraglutide, tirzepatide) produce significantly greater weight loss than placebo when combined with lifestyle modifications in adults and adolescents without type 2 diabetes.

If you have obesity and lifestyle changes haven't been enough, GLP-1 medications like semaglutide or tirzepatide are significantly more effective than placebo when combined with diet and exercise. Expect side effects like nausea, which are usually manageable, and commit to a treatment duration of at least 5-7 months to see full results.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg/week and liraglutide 3.0 mg/day) produce significant weight loss in adults with obesity (BMI ≥27 or ≥30) when combined with lifestyle modifications, outperforming placebo and many other pharmacotherapies.

If you have obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, GLP-1 agonists like semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are highly effective for weight loss when combined with diet and exercise. Semaglutide showed an average loss of 15.3 kg over 68 weeks in trials. Expect mild, temporary gastrointestinal side effects, but these rarely require stopping treatment. Oral options exist for those averse to injections.

GLP-1 receptor agonists (semaglutide 2.4 mg and liraglutide 3.0 mg) reduce energy intake by 34.5% and 13.0% respectively, leading to estimated body weight reductions of 17% and 8% at 20 weeks.

Clinical doses of GLP-1 agonists (semaglutide 2.4mg, liraglutide 3.0mg) significantly reduce energy intake, leading to substantial weight loss (8-17%) over 20 weeks. This effect is primarily driven by reduced food intake rather than just increased energy expenditure, and the model accounts for diminishing efficacy (tolerance) over time.

Anti-obesity medications (AOMs) cause disproportionate loss of lean mass (skeletal muscle), which may worsen frailty and functional capacity in heart failure patients, necessitating concurrent resistance training and protein intake.

When using GLP-1 or GLP-1/GIP medications for heart failure, be aware that you will lose muscle mass along with fat. To protect your strength and function, you MUST combine these medications with resistance training and ensure adequate protein intake. Monitor your functional capacity closely.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist that promotes weight loss and glycemic control through synergistic mechanisms including increased glucose-dependent insulin secretion, reduced glucagon, delayed gastric emptying, and increased satiety.

Tirzepatide is a powerful, weekly injectable medication for diabetes and obesity that works by mimicking hormones to control blood sugar and reduce appetite. It requires a prescription, medical supervision, and lifestyle changes (diet/exercise). Using it without medical oversight for aesthetic reasons is dangerous and contributes to drug shortages and fraud.

Dual incretin agonists (specifically GIP/GLP-1 co-agonists like tirzepatide) produce significantly greater weight loss and glycemic reduction than single GLP-1 receptor agonists, effectively closing the treatment gap between pharmacotherapy and bariatric surgery.

If standard GLP-1 medications (like semaglutide or liraglutide) are not delivering sufficient weight loss or blood sugar control, or if side effects prevent you from taking a higher dose, ask your doctor about dual agonists like tirzepatide. These medications target two hormones (GIP and GLP-1) simultaneously and have shown in clinical trials to produce significantly greater weight loss (up to 20%) and better blood sugar control than single-hormone drugs, often with a manageable side effect profile.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces significant weight loss (15-21%) in adults with obesity when administered weekly alongside lifestyle modifications.

If you have obesity or are overweight with related health issues, Tirzepatide is a once-weekly injection that works by mimicking hormones to reduce appetite and slow digestion. In clinical trials, patients lost 15-21% of their body weight over 72 weeks when combining the drug with diet and exercise. While nausea and diarrhea are common side effects, they affect a minority of users. This treatment is intended for long-term management, not short-term fixes.

GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce significant weight loss (5-21%) by suppressing appetite via central nervous system mechanisms and delaying gastric emptying, serving as effective pharmacological alternatives to surgery.

If diet and exercise aren't enough, GLP-1 drugs like Semaglutide (Wegovy) or Tirzepatide (Zepbound) are highly effective pharmacological options. They work by mimicking gut hormones to reduce hunger signals in the brain and slow down digestion. Semaglutide is taken once weekly, while Tirzepatide (a dual agonist) can lead to even greater weight loss (up to 21%). These require a prescription and lifestyle changes, and may cause gastrointestinal side effects like nausea.

Tirzepatide treatment for weight management produces significant weight loss (mean 22.6% over 36 weeks) accompanied by perceived improvements in appetite control, energy levels, and physical functioning, with gastrointestinal side effects being common but generally manageable.

Tirzepatide is a weekly injection approved for weight management in adults with obesity or overweight. Clinical data from the SURMOUNT-4 trial shows an average weight loss of 22.6% over 36 weeks. Patients report significant improvements in appetite control, energy, and physical functioning. Common side effects include nausea and diarrhea, which are often manageable. Most patients found the injection device easy to use and were willing to continue treatment.

Low Energy Availability (LEA) negatively impacts performance and health in both male and female athletes, causing reduced explosive power, endurance, and increased risk of injury and hormonal dysfunction.

Ensure your energy intake matches your expenditure. For both men and women, consuming too few calories relative to activity levels reduces strength, endurance, and increases injury risk. Monitor energy availability, aiming for >45 kcal/kg fat-free mass for healthy adults.

Carbohydrate periodization and strategic timing (loading, intra-exercise intake, post-exercise recovery) significantly support performance and recovery, whereas excessive protein intake above recommendations does not further improve performance.

For events over 90 minutes, use carbohydrate loading (10-12g/kg) 36-48 hours prior. During exercise, consume 30-60g carbs/hour (up to 90g for >2.5h). Post-exercise, prioritize carbs (1.2g/kg) if recovery time is short. Do not exceed protein recommendations as it offers no extra performance benefit.

Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training significantly improves lower-body dynamic power (jump height) compared to placebo.

If you want to improve your explosive power (like jumping), adding 300mg of PEA daily to your training routine might help. The study showed a significant improvement in jump height compared to a placebo, suggesting it may support power development alongside strength training.

Personalized nutrition targeting inflammation (PNi) significantly improves body weight, body fat, and inflammatory biomarkers (IL-10, TNF-α, CRP) specifically in individuals with a high genetic predisposition to inflammation (High-PGSi), whereas generic or carbohydrate-focused personalized diets do not yield these specific anti-inflammatory benefits in this subgroup.

If you have a family history of inflammatory conditions or obesity, generic 'healthy eating' advice might not be enough. This research suggests that identifying your genetic risk for inflammation (via a Polygenic Score) allows you to choose a specific anti-inflammatory diet (rich in specific oils, turmeric, and omega-3/6 fats) that can significantly improve your weight, body fat, and inflammatory markers. Without this genetic targeting, standard personalized diets may fail to reduce inflammation in high-risk individuals.

Superset resistance training (performing two exercises consecutively with minimal rest) yields equivalent muscular strength, hypertrophy, and body composition adaptations compared to traditional set training, while reducing total session time by approximately 36%.

If you are already experienced with resistance training, you can save about 36% of your gym time by using supersets (pairing two exercises back-to-back with no rest, then resting after the pair) instead of resting between every set. You will get the same muscle and strength gains, but you will feel more fatigued during the session. Ensure you still train to failure and adjust weights to keep reps in the 8-12 range.

Isometric training at long muscle lengths produces similar quadriceps femoris hypertrophy to full range of motion isotonic training in resistance-trained individuals.

If you want to build quad size, you don't necessarily need to do full squats or leg presses. You can use isometric holds at the bottom of the movement (long muscle length) for 30 seconds per set. Do 3-5 sets per session, twice a week, progressively adding sets over 6 weeks. This will build muscle just as well as traditional dynamic leg exercises, provided you are already trained in resistance training.

Adherence to a healthy vegan diet results in greater improvements in overall diet quality (HEI-2015) compared to a healthy omnivore diet, driven by higher intakes of fiber, legumes, and vegetables and lower intakes of added sugars and refined grains.

If you switch to a vegan diet, focus on increasing vegetables, legumes, nuts, seeds, and whole grains while reducing added sugars and refined grains. This study shows that a well-structured vegan diet can improve overall diet quality more than a healthy omnivore diet. Start with delivered meals or meal planning support to build skills, then transition to self-prepared meals. Ensure you monitor Vitamin B12 levels as intake drops without animal products.

Subcutaneous semaglutide 2.4 mg administered once weekly significantly reduces body weight and cardiometabolic risk factors (HbA1c, total cholesterol, systolic blood pressure) in East Asian adults with obesity compared to placebo, though it is associated with higher rates of adverse events.

For East Asian adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) combined with diet and exercise is a clinically effective treatment for significant body weight reduction and improvement in cardiometabolic risk factors like blood pressure and cholesterol. Patients should be aware that adverse events are more common than with placebo, but the clinical benefits are established.

Tirzepatide (a dual GLP-1RA/GIP agonist) produces superior mean weight loss (18.4%) compared to other FDA-approved pharmacotherapies for obesity, including semaglutide, phentermine-topiramate, and orlistat.

If you have obesity and lifestyle changes alone haven't worked, Tirzepatide is currently the most effective FDA-approved medication for weight loss, showing nearly 18% average weight loss in clinical trials. It requires weekly injections and careful dose titration to manage gastrointestinal side effects, but it offers superior results compared to older drugs like Orlistat or Phentermine-Topiramate.